A- A A+

Clinical practice guideline on pharmacological and psychological management of adult patients with an anxiety disorder and comorbid substance use. 

Sáiz PA, Flórez G, Arrojo M, Bernardo M, González-Pinto A, Goikolea JM, Zorrilla I, Cunill R, Castells X, Becoña E, López A, Torrens M, Fonseca F, Tirado-Muñoz J, Arranz B, Garriga M, San L. 

Adicciones. 2022 Apr 1;34(2):157-167. English, Spanish. doi: 10.20882/adicciones.1548. PMID: 34171105.

https://adicciones.es/index.php/adicciones/article/view/1548

Buprenorphine Uptake During Pregnancy Following the 2017 Guidelines Update on Prenatal Opioid Use Disorder. 

Nguemeni Tiako MJ, Meinhofer A, Friedman A, South EC, Epstein RL, Meisel ZF, Morgan JR. 

Am J Obstet Gynecol. 2022 May 22:S0002-9378(22)00392-1. doi: 10.1016/j.ajog.2022.05.041. Epub ahead of print. PMID: 35613648.

https://www.ajog.org/article/S0002-9378(22)00392-1/pdf

Schottland. Medication Assisted Treatment (MAT) standards: access, choice, support

Evidence based standards to enable the consistent delivery of safe, accessible, high-quality drug treatment across Scotland. These are relevant to people and families accessing or in need of services, and health and social care staff responsible for delivery of recovery oriented systems of care. (Scottish Government, Population Health Directorate, Schottland, 31.05.2021)

https://www.gov.scot/publications/medication-assisted-treatment-mat-standards-scotland-access-choice-support/pages/6/

Scoping Review of Best Practice Guidelines for Care in the Labor and Birth Setting of Pregnant Women Who Use Methamphetamines. 

Gulbransen K, Thiessen K, Pidutti J, Watson H, Winkler J. 

J Obstet Gynecol Neonatal Nurs. 2022 Mar;51(2):141-152. doi: 10.1016/j.jogn.2021.10.008. Epub 2021 Dec 13. PMID: 34914926.

https://www.jognn.org/article/S0884-2175(21)00305-1/fulltext

The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. 

Perry C, Liberto J, Milliken C, Burden J, Hagedorn H, Atkinson T, McKay JR, Mooney L, Sall J, Sasson C, Saxon A, Spevak C, Gordon AJ; VA/DoD Guideline Development Group*. 

Ann Intern Med. 2022 Mar 22. doi: 10.7326/M21-4011. Epub ahead of print. PMID: 35313113.

https://www.acpjournals.org/doi/full/10.7326/M21-4011

Schottland. National Wound Care Guide  - An introduction to recognising and assessing common wounds and injecting injuries in people who inject drugs

SDF – Scottish Drugs Forum, 2022

https://www.sdf.org.uk/wp-content/uploads/2022/02/National-Wound-Care-Guide.pdf

Expert Panel Consensus on Management of Advanced Cancer-Related Pain in Individuals With Opioid Use Disorder. 

Merlin JS, Khodyakov D, Arnold R, Bulls HW, Dao E, Kapo J, King C, Meier D, Paice J, Ritchie C, Liebschutz JM. 

JAMA Netw Open. 2021 Dec 1;4(12):e2139968. doi: 10.1001/jamanetworkopen.2021.39968. PMID: 34962565.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787463

Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. 

Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, Pacula RL, Rehm J, Room R, Brink WVD, Hall W. 

Int J Drug Policy. 2021 Aug 28:103381. doi: 10.1016/j.drugpo.2021.103381. Epub ahead of print. PMID: 34465496.

https://www.sciencedirect.com/science/article/pii/S0955395921002863

Telehealth for Opioid Use Disorder Toolkit: Guidance to Support High-Quality Care

The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional. (PCSS – Providers Clinical Support Systems und SAMHSA - Substance Abuse and Mental Health Services, USA, 2.10.2021)

https://pcssnow.org/wp-content/uploads/2021/10/OUD-Toolkit_FINAL_10.2021.pdf

USA. Speaking the Same Language: A Toolkit for Strengthening Patient-Centered Addiction Care in the United States

Why this Toolkit? Why Now?

In the face of the ongoing substance use disorder (SUD) crisis and rising overdose deaths, policymakers and other stakeholders continue seeking ways for improving SUD prevention and treatment services.  While highly effective treatments for SUD are available, outcomes achieved in community settings rarely approach those that can be achieved in the best designed treatment systems.  Historically, there has been significant heterogeneity across states and communities in the organization and oversight of addiction treatment systems.  This has contributed to high variability in the quality of care and resulting patient outcomes. (ASAM – American Society of Addiction Medicine, November 2021)

https://www.asam.org/asam-criteria/toolkit

Schottland. New National Resource around Opioid Agonist Treatment 

A new National Resource has been created focusing on Opioid Agonist Treatment (OAT).

This resource fits under Medication Assisted Treatment (MAT), but is specific to Opiate replacement/agonist treatment. (Scottish Drug Deaths Taskforce, Schottland, 02.11.2021)

https://drugdeathstaskforce.scot/news/opioid-agonist-treatment-oat-guidance-for-scotland/

EMCDDA releases new European miniguides on responding to drug problems 

What are the most effective treatment options for cannabis problems? How to respond to new trends in cocaine use? How to help prevent the non-medical use of medicines?

These are among the questions explored in a new collection of miniguides being launched today by the EU drugs agency (EMCDDA). The miniguides — being released in four successive bundles between October 2021 and early 2022 — focus on patterns of use, harms, settings and vulnerable groups. Together, they make up the agency’s latest overview of actions and interventions now available to respond to the consequences of illicit drug use. (EMCDDA, Lisbon 18.10.2021 (News release No 9/2021))

https://www.emcdda.europa.eu/news/2021/9/emcdda-releases-new-european-miniguides-responding-drug-problems_en

Treating Concurrent Substance Use Among Adults 

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD). (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, September 2021)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-06-02-002.pdf

EMCDDA. Implementing quality standards for drug services and systems: a six-step guide to support quality assurance

Summary

This publication provides a practical introduction to the area of quality standards and quality assurance mechanisms and the key steps involved in their implementation in drug services and systems. The primary audience for this guide is those responsible for commissioning, planning or providing quality assurance processes at the national or local level. It may also be of interest to recipients of interventions, service users or advocacy groups. (EMCDDA, Lissabon, September 2021)

https://www.emcdda.europa.eu/system/files/publications/14065/TDMA21003ENN.pdf

Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. 

Lintzeris N, Dunlop A, Masters D (2019) 

NSW Ministry of Health, Sydney Australia

https://www.health.nsw.gov.au/aod/Publications/full-depot-bupe-interim-gl.pdf

USA. TIP 63: Medications for Opioid Use Disorder - Executive Summary

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, 10.08.2021)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-003.pdf

USA. TIP 63: Medications for Opioid Use Disorder - For Healthcare and Addiction Professionals, Policymakers, Patients, and Families - Full Document

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, Juli 2021)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf

USA. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder - 2020 Focused Update

The ASAM National Practice Guideline 2020 focused update is intended to inform and empower clinicians, health system administrators, criminal justice system administrators, and policymakers who are interested in implementing evidence-based practices to improve outcomes for individuals with OUD. This is especially critical in the context of the ongoing COVID-19 emergency, which threatens to curtail patient access to evidence-based treatment.  

The document is an update to the previous NPG released in 2015 and includes major revisions to 35 existing recommendations, along with the addition of 13 new recommendations. 

This focused update was developed over the course of 14 months with consensus from an independent committee of experts and the use of a rigorous RAND/RAM methodology facilitated by researchers from Research Triangle Institute (RTI). (ASAM – American Society of Addiction Medicine)

https://www.asam.org/Quality-Science/quality/2020-national-practice-guideline

The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management

This clinical guideline provides the latest information to provide guidance on the identification and management of alcohol withdrawal in patients with varying degrees of syndrome severity. It is especially critical in the context of the ongoing COVID-19 emergency, which threatens to curtail patient access to evidence-based treatment.

https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf

UK. Guidance: Opioid substitution treatment: guide for keyworkers 

Advice for drug treatment and recovery workers to help them to deliver safe and effective OST to service users. (PHE – Public Health England, 21.07.2021)

https://www.gov.uk/government/publications/opioid-substitution-treatment-guide-for-keyworkers

UK. Guidance. Opioid substitution treatment: service self-assessment tool 

Self-assessment tool, good-practice examples and resources for community drug treatment services to help them deliver OST in line with clinical guidance. (PHE – Public Health England, 21.07.2021)

https://www.gov.uk/government/publications/opioid-substitution-treatment-service-self-assessment-tool

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department. 

Hawk K, Hoppe J, Ketcham E, LaPietra A, Moulin A, Nelson L, Schwarz E, Shahid S, Stader D, Wilson MP, D'Onofrio G. 

Ann Emerg Med. 2021 Jun 22:S0196-0644(21)00306-1. doi: 10.1016/j.annemergmed.2021.04.023. Epub ahead of print. PMID: 34172303.

https://www.annemergmed.com/article/S0196-0644(21)00306-1/fulltext

Interobserver agreement between emergency clinicians and nurses for Clinical Opiate Withdrawal Scale. 

Tomaszewski CA, Quenzer F, Corbett B, Lafree A, Lasoff D, Romo J, Mukau L. 

J Am Coll Emerg Physicians Open. 2021 Jun 18;2(3):e12462. doi: 10.1002/emp2.12462. PMID: 34179884; PMCID: PMC8212561.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212561/

Addiction Medicine Practice-Based Research Network (AMNet): Assessment Tools and Quality Measures. 

Clarke DE, Ibrahim A, Doty B, Patel S, Gibson D, Pagano A, Thompson L, Goldstein AB, Vocci F, Schwartz RP. 

Subst Abuse Rehabil. 2021 Jun 25;12:27-39. doi: 10.2147/SAR.S305972. PMID: 34211312; PMCID: PMC8240849.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240849/

Schottland. MAT Standards Informed Response for Benzodiazepine Harm Reduction 

Call to action The unprecedented harm associated with street benzodiazepines in Scotland is a public health emergency that demands a different approach. The false notion that postponing change in prescribing practice is the safest position and the current status quo,is unacceptable. The current rate of high levels of benzodiazepine related harm seen in Scotland qualify in the Orange Guidelinesas ‘exceptional circumstances’. We all have a responsibility to listento, assess and understand a person’s unique story of benzodiazepineuse to identify appropriate treatment and care. Initial conversations should address immediate risk of harm, particularly overdose and death. Conversations should be underpinned by principles of psychological and trauma informed care including safety, empowerment, choice, collaboration and trust, in line with the MAT standards (Appendix A). (SDF – Scottish Draugs Forum, Juki 2021)

http://www.sdf.org.uk/wp-content/uploads/2021/06/MAT-Standards-Informed-Response-for-Benozdiazepine-Harm-Reduction_interim-guidance_June21.pdf

Kanada. Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. 

Centre for Addiction and Mental Health. Canada. Published May 2021. 

https://www.camh.ca/-/media/files/professionals/canadian-opioid-use-disorder-guideline2021-pdf.pdf

SAMHSA. Telehealth for the Treatment of Serious Mental Illness and Substance Use Disorders

This guide reviews ways that telehealth modalities can be used to provide treatment for serious mental illness and substance use disorders among adults, distills the research into recommendations for practice, and provides examples of how these recommendations can be implemented.

SAMHSA – Substance Abuse and Mental Health Services Administration, USA, Publication ID PEP21-06-02-001, Publication Date: June 2021 

https://store.samhsa.gov/product/telehealth-for-treatment-serious-mental-illness-substance-use-disorders/PEP21-06-02-001

International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. 

Özgen H, Spijkerman R, Noack M, Holtmann M, Schellekens ASA, van de Glind G, Banaschewski T, Barta C, Begeman A, Casas M, Crunelle CL, Daigre Blanco C, Dalsgaard S, Demetrovics Z, den Boer J, Dom G, Eapen V, Faraone SV, Franck J, González RA, Grau-López L, Groenman AP, Hemphälä M, Icick R, Johnson B, Kaess M, Kapitány-Fövény M, Kasinathan JG, Kaye SS, Kiefer F, Konstenius M, Levin FR, Luderer M, Martinotti G, Matthys FIA, Meszaros G, Moggi F, Munasur-Naidoo AP, Post M, Rabinovitz S, Ramos-Quiroga JA, Sala R, Shafi A, Slobodin O, Staal WG, Thomasius R, Truter I, van Kernebeek MW, Velez-Pastrana MC, Vollstädt-Klein S, Vorspan F, Young JT, Yule A, van den Brink W, Hendriks V. 

Eur Addict Res. 2020;26(4-5):223-232. doi: 10.1159/000508385. Epub 2020 Jul 7. PMID: 32634814.

https://www.karger.com/Article/FullText/508385

Schottland. Drug Medication Assisted Treatment (MAT) standards: access, choice, support

Evidence based standards to enable the consistent delivery of safe, accessible, high-quality drug treatment across Scotland. These are relevant to people and families accessing or in need of services, and health and social care staff responsible for delivery of recovery oriented systems of care. (Scottish Government, Population Health Directorate, 31.05.2021)

https://www.gov.scot/publications/medication-assisted-treatment-mat-standards-scotland-access-choice-support/

Guidelines for Partnering with People with Lived and Living Experience of Substance Use and Their Families and Friends 

Canadian Centre on Substance Use and Addiction, 2021

https://ccsa.ca/sites/default/files/2021-04/CCSA-Partnering-with-People-Lived-Living-Experience-Substance-Use-Guide-en.pdf